Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

  • 📰 Reuters
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agree...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Degli inglesi , posso anche fregarmene. Ormoni o senza , sono sempre loro.

Greed.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billionU.K.-based GlaxoSmithKline Plc and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday.
Source: MarketWatch - 🏆 3. / 97 Read more »

Merck named the best pharma stock by Bank of AmericaBank of America named Merck its top pick among the many U.S. pharmaceutical stocks thanks to the growing success of its key cancer drug.
Source: CNBC - 🏆 12. / 72 Read more »

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billionU.K.-based GlaxoSmithKline Plc and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday.
Source: MarketWatch - 🏆 3. / 97 Read more »